Meetings
From 2008.igem.org
m |
|||
(25 intermediate revisions not shown) | |||
Line 4: | Line 4: | ||
<font face="Arial Rounded MT Bold" style="color:#010369">_meetings</font></div> | <font face="Arial Rounded MT Bold" style="color:#010369">_meetings</font></div> | ||
<br><br> | <br><br> | ||
- | + | ;April 24th 2008 <br> | |
- | ; | + | Recruitment of team<br> |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
;May 8th 2008 <br> | ;May 8th 2008 <br> | ||
- | ''' | + | '''attendees'''<br> |
Philipp Mappes, Wolfgang Schamel, Kilian Bartholomé, Katja Arndt, Kristian Müller, Dario Hermida Aponte, Normann Kilb, Robert Gawlik, Simone Weber, Veronika Götz, Kristina Brückner, Kathrin Pieper, Michael Kneib, Moritz Busacker, Sabine Jägle | Philipp Mappes, Wolfgang Schamel, Kilian Bartholomé, Katja Arndt, Kristian Müller, Dario Hermida Aponte, Normann Kilb, Robert Gawlik, Simone Weber, Veronika Götz, Kristina Brückner, Kathrin Pieper, Michael Kneib, Moritz Busacker, Sabine Jägle | ||
- | ''' | + | '''How to organize the project?''' <br> |
- | + | The DNA origamis shall be tested on the established T-cell system. Then we will try to establish an artificial system. Extracellular fragments could be the EGFR or Fas for example. Since the Fas receptor is involved in apoptosis, signaltransduction could be detectable by cell death. Further systems for detecting signaltransduction could be NF-kappaB, the MAP-Kinase-pathway, the Jun-Fos-system or splitenzymes.<br> | |
- | + | '''DNA-origami structure'''<br> | |
- | + | How expensive will the synthesis of the NIP coupled Oligos be? Phillip and Michael will contact the company and ask for an calculation of costs. NIP can be ordered by the company Biosearch technology.<br> | |
- | ''' | + | '''Controls for the DNA origamis'''<br> |
- | + | * We should produce a DNA origami without NIP-coupled Oligos to check if there also a cell binding occurs (negative control)<br> | |
- | + | * To check the calculated distances between the NIP's on the origami, DNA-origami with fluorophores could be made. By using FRET the distance between the oligo's can be estimated.<br> | |
- | ''' | + | <br> |
- | * | + | |
- | * | + | |
- | + | ||
- | + | ||
- | + | ||
;May 23th 2008 | ;May 23th 2008 | ||
- | |||
- | |||
;Jun 2th 2008 <br> | ;Jun 2th 2008 <br> | ||
- | ''' | + | '''attendees'''<br> |
Sabine Jägle, Normann Kilb, Robert Gawlik, Kristian Müller, Philipp Mappes | Sabine Jägle, Normann Kilb, Robert Gawlik, Kristian Müller, Philipp Mappes | ||
- | ''' | + | '''We have talked about...'''<br> |
- | * | + | * To ensure an optimal NIP-scFV-Anti-NIP binding a longer NIP-Linker should be used |
- | * NIP | + | * Calculated distances between the NIP's are 6-7 nm. |
- | * | + | * Integration of the TCR in the model to achieve a comparison of the sizes |
- | * | + | * Searching a suitable transmembraneregion for the artificial receptor |
- | * | + | * Calculation of costs for 10 Oligos wirh NIP coupled to the 5' or 3'-end: 3000,-US$ at uncertain coupling efficiency |
- | * => | + | * => Order presumably from PURIMEX |
;Jun 13th 2008 | ;Jun 13th 2008 | ||
- | ''' | + | '''attendees'''<br> |
Michael Kneib, Robert Gawlik, Philipp Mappes, Simone Weber, Kristina Brückner, Sabine Jägle, Kathrin Pieper | Michael Kneib, Robert Gawlik, Philipp Mappes, Simone Weber, Kristina Brückner, Sabine Jägle, Kathrin Pieper | ||
- | ''' | + | '''Ordering of NIPs'''<br> |
- | + | Assembly of the DNA origami with coupled NIPs was discussed and decided: | |
[[image:Freiburg08_NIP_13_06_08.jpg]] | [[image:Freiburg08_NIP_13_06_08.jpg]] | ||
- | + | Question: What are the exact distances between the DNA-helices/nod-points? --> Rothemund <br> | |
- | ''' | + | '''The next steps'''<br> |
- | - | + | - searching for literature on TCR-Clustering<br> |
- | - | + | - searching for literature on transmembrane-helices, signal sequences<br> |
- | - | + | - planning of the artificial system with antibodyfragment, transmembraneregion, splitenzymes, enzyme assay<br> |
- | - EGFR | + | - EGFR as further test-system<br> |
- | ; | + | ;Jun 16th 2008 10.00h |
- | + | Preparation of intern presentation on Tuesday | |
- | ; | + | ;Jun 17th 2008 12.00h |
- | ''' | + | '''We have talked about...'''<br> |
- | - | + | - Until Friday we will order the NIP-coupled-Oligos. Consultation of Mahima: Philipp<br> |
- | - | + | - We should organize to get the vectors for cloning (Dinah/Christina: Vector with CMV-Promoter) --> Kathrin <br> |
- | - Schamels | + | - Reproduce Schamels experiment with the TCR --> appointment with Mahima<br> |
- | - | + | - Think about a cloning strategy using the BioBrick pre- and suffix <br> |
- | - | + | - Literature transmembranhelices WF DeGrado<br> |
- | - | + | - Programme for cloning: Emboss (emboss.org)<br> |
<br> | <br> | ||
- | ; | + | ;Jun 23rd 2008 12.00h |
<div class=Section1> | <div class=Section1> | ||
- | <p class=MsoNormal style='margin-left:18.0pt'><b> | + | <p class=MsoNormal style='margin-left:18.0pt'><b>attendees</b></p> |
<p class=MsoNormal style='margin-left:18.0pt'>Robert Gawlik, Philipp Mappes, | <p class=MsoNormal style='margin-left:18.0pt'>Robert Gawlik, Philipp Mappes, | ||
Line 100: | Line 85: | ||
<p class=MsoNormal style='margin-left:18.0pt'> </p> | <p class=MsoNormal style='margin-left:18.0pt'> </p> | ||
- | <p class=MsoNormal style='margin-left:18.0pt'><b> | + | <p class=MsoNormal style='margin-left:18.0pt'><b>We have talked about...</b></p> |
<p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | <p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | ||
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span>Oligos | + | </span></span>Oligos are ordered. They should be delivered until the 10th of July.</p> |
- | + | ||
<p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | <p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | ||
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Transmembraneregion: </p> |
<p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | ||
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Literature about the transmembraneregion</p> |
<p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | ||
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Which transmembraneregion can be used? For example EGF-R</p> |
<p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | ||
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Signalpeptide?!</p> |
<p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | ||
Line 130: | Line 114: | ||
<p class=MsoNormal style='margin-left:27.0pt;text-indent:-11.35pt'><span | <p class=MsoNormal style='margin-left:27.0pt;text-indent:-11.35pt'><span | ||
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span><span lang=EN-GB> | + | </span></span><span lang=EN-GB>synthetic transmembraneregion: </span></p> |
<p class=MsoNormal style='margin-left:90.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:90.0pt;text-indent:-18.0pt'><span | ||
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Which parts shall build the synthetic receptor?</p> |
- | + | ||
<p class=MsoNormal style='margin-left:72.0pt'> </p> | <p class=MsoNormal style='margin-left:72.0pt'> </p> | ||
Line 141: | Line 124: | ||
<p class=MsoNormal style='margin-left:27.0pt;text-indent:-11.35pt'><span | <p class=MsoNormal style='margin-left:27.0pt;text-indent:-11.35pt'><span | ||
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span><span lang=EN-GB> | + | </span></span><span lang=EN-GB>Vectors: </span></p> |
<p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | ||
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Genemaps for the Vectors</p> |
<p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | ||
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Available Vectors have to be compared to the iGEM-Systeme(Freiburg2007-WIKI)</p> |
- | + | ||
<p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | <p class=MsoNormal style='margin-left:54.0pt;text-indent:-18.0pt'><span | ||
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>possibly searching suitable vectors</p> |
<p class=MsoNormal><span lang=EN-GB> </span></p> | <p class=MsoNormal><span lang=EN-GB> </span></p> | ||
- | <p class=MsoNormal style='margin-left:15.65pt'><b><span lang=EN-GB> | + | <p class=MsoNormal style='margin-left:15.65pt'><b><span lang=EN-GB>jobs</span></b></p> |
<p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | <p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | ||
lang=IT style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | lang=IT style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span><span lang=IT> | + | </span></span><span lang=IT>Literature transmembraneregion/signalepeptide </span><span |
lang=EN-GB style='font-family:Wingdings'>:</span><span lang=IT> Simone, Kristina, | lang=EN-GB style='font-family:Wingdings'>:</span><span lang=IT> Simone, Kristina, | ||
Sabine</span></p> | Sabine</span></p> | ||
Line 168: | Line 150: | ||
<p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | <p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | ||
lang=IT style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | lang=IT style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span><span lang=EN-GB> | + | </span></span><span lang=EN-GB>Vectorsequences </span><span lang=EN-GB |
style='font-family:Wingdings'>:</span><span lang=EN-GB> Philipp, Kathrin, | style='font-family:Wingdings'>:</span><span lang=EN-GB> Philipp, Kathrin, | ||
Michael</span></p> | Michael</span></p> | ||
Line 174: | Line 156: | ||
<p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | <p class=MsoNormal style='margin-left:29.35pt;text-indent:-11.35pt'><span | ||
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'> | ||
- | </span></span> | + | </span></span>Registry on the official WIKI<span |
lang=EN-GB style='font-family:Wingdings'>:</span>Robert</p> | lang=EN-GB style='font-family:Wingdings'>:</span>Robert</p> | ||
</div> | </div> | ||
<br /> | <br /> | ||
- | ; | + | ;July 3rd 12.00h |
- | ''' | + | '''attendees''' <br> |
Robert Gawlik, Michael Kneib, Kathrin Pieper, Simone Weber, Daniel Hautzinger, Sabine Jägle, Philipp Mappes, Kristian Müller | Robert Gawlik, Michael Kneib, Kathrin Pieper, Simone Weber, Daniel Hautzinger, Sabine Jägle, Philipp Mappes, Kristian Müller | ||
- | '''1. | + | '''1. Vectors'''<br> |
- | Philipp | + | Philipp and Kathrin have worked with GCG. In doing so they saw that the fab fragment has iGEM restriction side. The vector from Christina, which we wanted to use, has also 7 iGEM restrictions sides.<br> |
- | + | We could mutagenesis or gensynthesis to get the iGEM restrictions sides. Genart is offering a special price for gen synthesis. If we want to use this special offer, we have to check which vector they use. It is important that their vector has not any of the iGEM restrictions sides (EcoRI, XbaI, SpeI, PstI) and non of ours restriction sides(NgoMIV, AgeI).<br> | |
- | + | All of the sequences from Mahima arrived by now and they can be checked. A vector wiith CMV-promotor could be also saerched on the wiki 2007.<br> | |
- | + | ||
- | '''2. | + | '''2. concentration of DNA structure'''<br> |
- | + | theoretically possible: 20 nM, maybe even 200 nM; according we need at least 2 µM to distinct between 2, 3 or 4 NIPs<br> | |
- | '''3. DNA | + | '''3. DNA-Origami'''<br> |
- | * | + | * binding measurement: Origami with 4 NIP molecules and 2 fluorophores<br> |
- | * | + | * negative control: DNA-Origami without NIP but with fluorophores<br> |
- | * Michael, Simone | + | * Michael, Simone and Daniel: preparation of M13 phage DNA and assessment of oligo-pool<br> |
- | '''4. | + | '''4. proof of principle: T-cell-receptor activation'''<br> |
- | * Ca- | + | * Ca-measurement at 530 nm<br> |
- | * GFP | + | * GFP-marker: detection of product after 12 to 18 hours; maybe we can measure FACS at the universities hospital?<br> |
- | '''5. | + | '''5. confocal microscopy''' |
- | * | + | *the MPI requires the absolvation of a training, we don´t have time for that;<br> |
- | * | + | *wavelength 488nm and 568nm might be measured at another lab<br> |
- | '''6. | + | '''6. "in general"'''<br> |
- | * | + | * upload more data onto the intern wiki<br> |
- | * | + | * meet more frequently |
- | * | + | * protocol/write labjournal on wiki |
- | * | + | * precise documentation of every generated sample<br> |
- | ''' | + | '''July 10th, 2008''' |
- | + | Attendees: | |
<p><font face="Arial">Simone Weber, Sabine Jägle, Kathrin Pieper, Phillip Mappes, | <p><font face="Arial">Simone Weber, Sabine Jägle, Kathrin Pieper, Phillip Mappes, | ||
Norman Kilb, Robert Gawlik, Daniel Hautzinger, Michael Kneib, Kristian Müller, | Norman Kilb, Robert Gawlik, Daniel Hautzinger, Michael Kneib, Kristian Müller, | ||
Kristina Brückner</font></p> | Kristina Brückner</font></p> | ||
<p> </p> | <p> </p> | ||
- | <p><font face="Arial"><b>1. | + | <p><font face="Arial"><b>1. Security instruction</b></font></p> |
- | <p><font face="Arial"><b>> </b> | + | <p><font face="Arial"><b>> </b>emergency call: 2000</font></p> |
- | <p><font face="Arial"><b>2. | + | <p><font face="Arial"><b>2.actual state of affairs</b></font></p> |
<ul> | <ul> | ||
- | <li><font face="Arial"> | + | <li><font face="Arial">M13mp18 phage DNA was preped</font></li> |
- | <li><font face="Arial"> | + | <li><font face="Arial">The Oligios we ordered arrived --> A poll was made, the pool contains all the Oligos except of the 10 which are to be marked with NIP or fluorophor </font></li> |
- | + | <li><font face="Arial">Ca<sup>2+</sup> - Daniels experiment (making DNA-Origami 1:20 has been reproduced, but we have to check on the AFM if the Origami formed right -> AFM measurement is tomorrow.</font></li> | |
- | + | <li><font face="Arial">We have to reorder some of the Oligo</font></li> | |
- | + | ||
- | + | ||
- | <li><font face="Arial"> | + | |
</ul> | </ul> | ||
- | <p><font face="Arial"><b>3. | + | <p><font face="Arial"><b>3. We need to solve the Origami-concentration problem</b></font></p> |
<ul> | <ul> | ||
- | <li><font face="Arial">Ca<sup>2+</sup> | + | <li><font face="Arial">Ca<sup>2+</sup>We could measure the calcium influx with a flourescence microscope. Therefore we have to find out which dye to use</font></li> |
- | + | ||
- | + | ||
- | + | ||
</ul> | </ul> | ||
- | <p><font face="Arial"><b>4. | + | <p><font face="Arial"><b>4. Think about the synthetic receptor system</b></font></p> |
<ul> | <ul> | ||
- | <li><font face="Arial"> | + | <li><font face="Arial">we could use a vector which already has the beta-chain of the TCR coupled to the NIP fab fragment and fuse half of β-Lactamase to each of it</font></li> |
- | + | <li><font face="Arial">if the receptors get clustered by the NIP the β-Lactamase would be functional </font></li> | |
- | + | ||
- | + | ||
- | <li><font face="Arial"> | + | |
- | + | ||
</ul> | </ul> | ||
- | <p><b><font face="Arial">5. | + | <p><b><font face="Arial">5. substrates for the β-Lactamase</font></b></p> |
<ul> | <ul> | ||
- | <li><font face="Arial"> | + | <li><font face="Arial">have to be ordered</font></li> |
- | <li><font face="Arial"> | + | <li><font face="Arial">Norman will get some information about diffrent β-Lactamase and order it </font></li> |
</ul> | </ul> | ||
- | <p><b><font face="Arial">6. | + | <p><b><font face="Arial">6. Transfection Protocol</font></b></p> |
<ul> | <ul> | ||
- | <li><font face="Arial">in Kristians | + | <li><font face="Arial">available in Kristians lab</font></li> |
</ul> | </ul> | ||
- | <p><b><font face="Arial">7. | + | <p><b><font face="Arial">7. Positive control for the transfections</font></b></p> |
<ul> | <ul> | ||
- | <li><font face="Arial">Norman | + | <li><font face="Arial">Norman will read about it</font></li> |
</ul> | </ul> | ||
- | <p><b><font face="Arial">8. | + | <p><b><font face="Arial">8. Searching other vectores</font></b></p> |
<ul> | <ul> | ||
- | <li><font face="Arial"> | + | <li><font face="Arial">Call Tollbox Freiburg</font></li> |
</ul> | </ul> | ||
- | <p><b><font face="Arial">9. | + | <p><b><font face="Arial">9. second system for multimerisation with different antibodieszweitesn</font></b></p> |
- | + | ||
<ul> | <ul> | ||
<li><font face="Arial">Antifluorescin-Antikalin (Arne Skerra) --> | <li><font face="Arial">Antifluorescin-Antikalin (Arne Skerra) --> | ||
- | + | Publication in literature!</font></li> | |
- | <li><font face="Arial">Andreas Blukthuhn (?) --> Dapin (> Kristian | + | <li><font face="Arial">Andreas Blukthuhn (?) --> Dapin (> Kristian will ask him)</font></li> |
- | + | ||
</ul> | </ul> | ||
- | <p><font face="Arial"><b>10. | + | <p><font face="Arial"><b>10. intracellular domain of EGF-R</b></font></p> |
<ul> | <ul> | ||
- | <li><font face="Arial"> | + | <li><font face="Arial"> http://www.ebi.ac.uk |
--> SRS --> Uniprot</font></li> | --> SRS --> Uniprot</font></li> | ||
- | <li><font face="Arial"> | + | <li><font face="Arial"> http://www.expasy.ch |
--> swissprot</font></li> | --> swissprot</font></li> | ||
- | <li><font face="Arial">Michael | + | <li><font face="Arial">Michael will read about it</font></li> |
</ul> | </ul> | ||
<p> </p> | <p> </p> | ||
<br> | <br> | ||
- | <p><font face="Arial"><b> | + | <p><font face="Arial"><b> July 16th 2008 12.00h</b></font></p> |
- | ''' | + | '''Attendees:''' <br> |
Robert Gawlik, Michael Kneib, Kathrin Pieper, Simone Weber, Moritz Busacker, Sabine Jägle, Philipp Mappes, Kristian Müller<br> | Robert Gawlik, Michael Kneib, Kathrin Pieper, Simone Weber, Moritz Busacker, Sabine Jägle, Philipp Mappes, Kristian Müller<br> | ||
'''1. DNA-Origami:''' <br> | '''1. DNA-Origami:''' <br> | ||
- | + | We reproduced the experiment of Daniel(Origami 1:20). Now we want to test, if we able to form also Origami when we use less Oligos (ratio 1:10, ratio 1:5) <br> | |
- | + | We have to test, if it is possible to use Krebs-Ringer-Hepes buffer for the calcium imaging<br> | |
- | + | We will also produce some Origami coupled with Alexa 488 for first binding measurements. therefore we have also to check were we could measure Alexa 488<br> | |
- | + | ||
- | ''' | + | '''Vectors and synthetic receptor system: '''<br> |
- | + | still we have not any vector which we can use for the clonings -> we have to check the vector of the Ljubljana-Projekt 2007<br> | |
- | + | Those parts should be planed and ordered:<br> | |
- | + | ||
-Fab-Singlechain<br> | -Fab-Singlechain<br> | ||
- | - | + | -Which signal sequence coats for the transmembrane domain<br> |
- | - | + | -Which transmembran region will we use?<br> |
- | - | + | -The transmembrane region could be attached to split-fluorophors, so the receptor clustering could be detected in a fluorescence microscope<br> |
- | + | - Which linker will we use?<br> | |
- | + | - We should talk to Tillmann Brunner, ZBSA about using the EGFR<br> | |
<br> | <br> | ||
<br> | <br> | ||
+ | <br> | ||
+ | <br> | ||
+ | '''July 23rd 2008 12.00h'''<br> | ||
+ | <br> | ||
+ | <span style="font-weight: bold;">Attendees</span> <br> | ||
+ | Robert Gawlik, Philipp Mappes, Kathrin Pieper,Sabine Jägle, | ||
+ | Simone Weber.<br> | ||
+ | <br> | ||
+ | <span style="font-weight: bold;">EGF-Receptor (EGFR):</span><br> | ||
+ | <ul> | ||
+ | <li>The T-cell surface has a lot of big molecules on the surface. Those molecules are much bigger than the receptor itself, therefore they could disturb the interaction between the ligand (e.g. Origami) and the receptor. | ||
+ | -> We should think about using the EGFR as receptor for our clonings, because this one has a relatively big extra cellular domain.</li> | ||
+ | </ul> | ||
+ | <ul> | ||
+ | <li>Not only a part of the EGFR could be used but the whole receptor, which is additionally linked to the NIP fab fragment by a long linker. So the ligand binding domain should be as big as the surface molecules.</li> | ||
+ | </ul> | ||
+ | <ul> | ||
+ | <li> This 3 constructs could be cloned:</li> | ||
+ | </ul> | ||
+ | <div style="margin-left: 40px;">1)EGFR + Single chain + one half of beta-Lactamase</div> | ||
+ | <div style="margin-left: 40px;">2)EGFR + Single chain + second half of beta-Lactamase</div> | ||
+ | <div style="margin-left: 40px;">3)The whole EGFR fused to the NIP fab fragment. With this construct it might be also possible to activate the receptor by adding EGF. Hence we would have a additionally positive control. But first we would have to find a readout for the activation with EGF.<br> | ||
+ | </div> | ||
+ | <span style="font-weight: bold;">Fura 2/ Indo-1:</span> | ||
+ | <br> | ||
+ | <ul> | ||
+ | <li>Both could be used for the Ca2+ signalling. Indo is often used for measurements on the FACS.</li> | ||
+ | </ul> | ||
+ | <ul> | ||
+ | <li>We will use Fura-2-AM for the measurements on the microscope.</li> | ||
+ | </ul> | ||
+ | <ul> | ||
<br> | <br> | ||
'''Aug. 7th 2008 ''' | '''Aug. 7th 2008 ''' | ||
- | <span style="font-weight: bold;"> | + | <span style="font-weight: bold;">Attendees:</span> <br> |
Robert Gawlik, Philipp Mappes, Normann Kilb, Sabine Jägle, | Robert Gawlik, Philipp Mappes, Normann Kilb, Sabine Jägle, | ||
- | Kristian Müller, Moritz | + | Kristian Müller, Moritz Busacker.<br> |
<ul> <li> '''problem:''' Where is the next Ca2+ measurement? </ul> | <ul> <li> '''problem:''' Where is the next Ca2+ measurement? </ul> | ||
<ul> <li> Take data of the Ca2+-measurement from Prof. Schamel. Titration to get the right concentration?</ul> | <ul> <li> Take data of the Ca2+-measurement from Prof. Schamel. Titration to get the right concentration?</ul> | ||
Line 324: | Line 325: | ||
'''Aug. 28th 2008'''<br> | '''Aug. 28th 2008'''<br> | ||
- | <br> | + | <br><br> |
- | + | ||
'''Sept. 11th 2008'''<br> | '''Sept. 11th 2008'''<br> | ||
Line 337: | Line 337: | ||
<body> | <body> | ||
<span style="font-weight: bold;">Attendees:</span> | <span style="font-weight: bold;">Attendees:</span> | ||
- | Sabine Jägle, | + | Sabine Jägle, Philipp Mappes, Norman Kilb, Christian Müller, |
Wolfgang Schamel, Simone Weber<br> | Wolfgang Schamel, Simone Weber<br> | ||
<br> | <br> | ||
Line 351: | Line 351: | ||
to amplificate it.<br> | to amplificate it.<br> | ||
</li> | </li> | ||
- | <li>Prove | + | <li>Prove if we used the right primer.</li> |
<li>Turn the temperature down a bit.</li> | <li>Turn the temperature down a bit.</li> | ||
<li>Use a positive control to be sure the polymerase and buffer | <li>Use a positive control to be sure the polymerase and buffer | ||
Line 442: | Line 442: | ||
<br><br> | <br><br> | ||
'''Sept. 24th. 2008'''<br> | '''Sept. 24th. 2008'''<br> | ||
- | + | <br> | |
- | + | -Modeling<br> | |
+ | -measurement of fura-stained T-and B-cells (ZBSA)<br> | ||
+ | -AFM-measurement at IMTEK?<br> | ||
+ | -consult MPI concerning antibody B1-8<br> | ||
+ | -cloning: CMV+YFP transfection control positive<br> | ||
+ | -order new oligos, this time modified with FluA aswell<br> | ||
'''Sept. 29th 2008'''<br> | '''Sept. 29th 2008'''<br> | ||
- | + | <br> | |
+ | -forms for traveling on "company" (university) business have to be filled in<br> | ||
+ | -deadlines for short description of the project and standard variance request are close<br> | ||
+ | -can we "digest" (papain/pepsin) the B1-8 IgM pentameres to visualize the antigen pattern on the origami under the AFM?<br> | ||
+ | -received synthesis from GeneArt and ATG:biosynthetics<br> | ||
+ | -FACS still doesn´t show positive results, amount of origami seems still too low<br< | ||
+ | -organization of hotel rooms at special rate<br> | ||
'''Oct. 7th 2008''''<br> | '''Oct. 7th 2008''''<br> | ||
- | + | <br> | |
Line 459: | Line 470: | ||
'''Final report''' | '''Final report''' | ||
<ul> | <ul> | ||
- | <li> structure equal to | + | <li> structure maybe equal to scientific paper, containing Abstract, Introduction, Materials and Methods, Results</li> |
<li> fusion of all sections we worked in: Origami, AFM, FACS, CA<sup>2+</sup>/Fura measuremt, cell cultures, modeling, ethics</li> | <li> fusion of all sections we worked in: Origami, AFM, FACS, CA<sup>2+</sup>/Fura measuremt, cell cultures, modeling, ethics</li> | ||
<li> quotation of literature through autor and year of publication in the text (Max Muster, 2007), full quotation in references in the end</li> | <li> quotation of literature through autor and year of publication in the text (Max Muster, 2007), full quotation in references in the end</li> | ||
Line 480: | Line 491: | ||
'''attendees:<br>''' | '''attendees:<br>''' | ||
- | Moritz | + | Moritz Busacker, Philipp Mappes, Kristian Müller, Normann Kilb, Robert Gawlik, Michael Kneib, Kathrin Pieper, Simone Weber<br> |
<br> | <br> | ||
Line 488: | Line 499: | ||
construcs: <br> | construcs: <br> | ||
<br> | <br> | ||
- | pMA - | + | pMA - signal peptide – scFv-anti-NIP – gggs-Linker – transmembrane region(BCR/EGFR) - '''X''' – pMA<br><br> |
'''X :''' | '''X :''' | ||
* bla1(1/2 beta-Lactamase)-<br> | * bla1(1/2 beta-Lactamase)-<br> | ||
Line 501: | Line 512: | ||
<br> | <br> | ||
'''Next steps:''' <br> | '''Next steps:''' <br> | ||
- | 1) We want to test | + | 1) We want to test wheather the transmembrane region really is located in the membrane<br> |
- | Therefore we want to clone a | + | Therefore we want to clone a construct expressing YFP on the cytoplasmic side of the receptor.<br> |
Construct:<br> | Construct:<br> | ||
- | - | + | - singal peptide – scFv-anti-NIP – gggs-Linker – transmembrane region - split-linker - bla1 - YFP -<br> |
<br> | <br> | ||
- | 2) We also want to test | + | 2) We also want to test if we able to bring the receptors together using a NIP coupled peptide.<br> |
Therefore we need the peptides from Schamels group -> Norman will ask them.<br> | Therefore we need the peptides from Schamels group -> Norman will ask them.<br> | ||
<br> | <br> | ||
Line 512: | Line 523: | ||
Have to produce new Origami -> Michael and Norman<br> | Have to produce new Origami -> Michael and Norman<br> | ||
<br> | <br> | ||
- | Next meeting: Oct. 23th 2008<br> | + | <!--Next meeting: Oct. 23th 2008<br>--> |
<br> | <br> | ||
}} | }} |
Latest revision as of 01:30, 20 November 2008
_meetings
Recruitment of team
attendees How to organize the project?
attendees We have talked about...
attendees Ordering of NIPs Question: What are the exact distances between the DNA-helices/nod-points? --> Rothemund The next steps
Preparation of intern presentation on Tuesday
We have talked about... - Until Friday we will order the NIP-coupled-Oligos. Consultation of Mahima: Philipp
attendees Robert Gawlik, Philipp Mappes, Michael Kneib, Kathrin Pieper, Sabine Jägle, Kristina Brückner, Simone Weber
We have talked about... · Oligos are ordered. They should be delivered until the 10th of July. · Transmembraneregion: o Literature about the transmembraneregion o Which transmembraneregion can be used? For example EGF-R o Signalpeptide?! o Paper: Erythropoitetin Receptor Activation by a Ligand-Induced Conformation Change · synthetic transmembraneregion: o Which parts shall build the synthetic receptor?
· Vectors: o Genemaps for the Vectors o Available Vectors have to be compared to the iGEM-Systeme(Freiburg2007-WIKI) o possibly searching suitable vectors
jobs · Literature transmembraneregion/signalepeptide : Simone, Kristina, Sabine · Vectorsequences : Philipp, Kathrin, Michael · Registry on the official WIKI:Robert
attendees 1. Vectors 2. concentration of DNA structure 3. DNA-Origami
4. proof of principle: T-cell-receptor activation
5. confocal microscopy
6. "in general"
July 10th, 2008 Attendees: Simone Weber, Sabine Jägle, Kathrin Pieper, Phillip Mappes, Norman Kilb, Robert Gawlik, Daniel Hautzinger, Michael Kneib, Kristian Müller, Kristina Brückner
1. Security instruction > emergency call: 2000 2.actual state of affairs
3. We need to solve the Origami-concentration problem
4. Think about the synthetic receptor system
5. substrates for the β-Lactamase
6. Transfection Protocol
7. Positive control for the transfections
8. Searching other vectores
9. second system for multimerisation with different antibodieszweitesn
10. intracellular domain of EGF-R
July 16th 2008 12.00h Attendees: Vectors and synthetic receptor system:
1)EGFR + Single chain + one half of beta-Lactamase
2)EGFR + Single chain + second half of beta-Lactamase
3)The whole EGFR fused to the NIP fab fragment. With this construct it might be also possible to activate the receptor by adding EGF. Hence we would have a additionally positive control. But first we would have to find a readout for the activation with EGF.
Fura 2/ Indo-1:
Aug. 7th 2008 Attendees: Robert Gawlik, Philipp Mappes, Normann Kilb, Sabine Jägle, Kristian Müller, Moritz Busacker.
brochure for further information [http://tools.invitrogen.com/content/sfs/manuals/liveblazer_FRETBGLoadingKit_man.pdf brochure_liveblazer_FRETBGLoadingKit]
Aug. 28th 2008 Sept. 11th 2008
Themes: 1. CMV Promotor Sabine tried to amplificate the CMV Promotor (in the vector) -> it didn’t work! Improvements: 2. Antibodies Probably we could get some antibodies against NIP from Schamel and his group, so we could proof if our origamis have the NIP. Normally we could see the antibodies on the AFM. 3. FACS We measured the calcium influx on the FACS. 4. Fura-Loading Because the Fura stain didn´t work when we tried to measure the calcium influx at the microscope (ZBSA), we wanted to repeat the staining to see what we should change. o Again the staining didn´t work -> We have to ask Nitschke about the conditions. o We also have to order the Fura-2AM. 5. NIP binding to the cells We also repeated the binding measurement at the microscope. -> We can get the B-cells(2558Lδm/mb-1) from Schamel!
attendees organisatory Ca-measurement Wiki part-order control of DNA-Origami binding to cell-surface
Sept. 29th 2008
official wikipediasite iGEM parts
attendees:
|